Bullock Jessica M, Lanaux Travis M, Shmalberg Justin W
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL.
Department of Comparative, Diagnostic, and Population Medicine, College of Veterinary Medicine, University of Florida, Gainesville, FL.
J Vet Emerg Crit Care (San Antonio). 2019 Mar;29(2):161-165. doi: 10.1111/vec.12813. Epub 2019 Feb 14.
To report the incidence of adverse events during euthanasia of client-owned dogs administered either intravenous pentobarbital/phenytoin (PP) or PP after propofol delivery.
DESIGN/SETTING: Prospective, observational, multi-site study.
Four hundred thirty-six dogs undergoing client-elected euthanasia over a 1-year period.
Interventions included placement of an IV catheter and delivery of euthanasia agents (PP for the PP group, propofol followed by PP for the propofol group). Seven pre-determined adverse events were recorded: agonal breaths, urination, defecation, vocalization, muscle activity, dysphoria, and catheter complications. Euthanasia scores for each patient were defined as the sum of all adverse events (0-7) the patient exhibited.
Two hundred thirty-six dogs were in the PP group and 200 dogs were in the propofol group. No significant differences were detected in the dose of PP administered (166.9 ± 105.6 mg/kg for PP group, 182.6 ± 109.8 mg/kg for propofol group). Propofol dogs received 4.5 ± 2.9 mg/kg propofol. The incidence of ≥ 1 adverse event was 35.2% in the PP group and 26.5% in the propofol group (P = 0.052). Mean euthanasia scores (0.47 PP group, 0.32 propofol group) were not significantly different (P = 0.08). Propofol significantly reduced the incidence of muscle activity (6% vs. 14%, odds ratio 0.39; P = 0.0079).
There was no difference in the likelihood of the studied adverse events during client-elected euthanasia in dogs when propofol was used prior to PP. There was a significant reduction in perimortem muscle activity if propofol was given prior to PP.
报告对客户拥有的犬实施安乐死过程中,静脉注射戊巴比妥/苯妥英钠(PP)或在给予丙泊酚后再给予PP时不良事件的发生率。
设计/地点:前瞻性、观察性、多中心研究。
在1年期间内436只接受客户选择安乐死的犬。
干预措施包括放置静脉导管和给予安乐死药物(PP组给予PP,丙泊酚组先给予丙泊酚再给予PP)。记录7种预先确定的不良事件:濒死呼吸、排尿、排便、发声、肌肉活动、烦躁不安和导管并发症。每位患者的安乐死评分定义为患者出现的所有不良事件(0 - 7分)的总和。
PP组有236只犬,丙泊酚组有200只犬。两组给予的PP剂量无显著差异(PP组为166.9±105.6mg/kg,丙泊酚组为182.6±109.8mg/kg)。丙泊酚组的犬接受了4.5±2.9mg/kg的丙泊酚。PP组中≥1种不良事件的发生率为35.2%,丙泊酚组为26.5%(P = 0.052)。平均安乐死评分(PP组为0.47,丙泊酚组为0.32)无显著差异(P = 0.08)。丙泊酚显著降低了肌肉活动的发生率(6%对14%,优势比0.39;P = 0.0079)。
在对犬进行客户选择的安乐死过程中,在PP之前使用丙泊酚时,所研究的不良事件发生的可能性没有差异。如果在PP之前给予丙泊酚,濒死期肌肉活动会显著减少。